Partnering For Precision In An IPF Study: Securing Timely Deliverables And Key Endpoints

A pharmaceutical company specializing in fibrotic diseases, particularly Idiopathic Pulmonary Fibrosis (IPF), sought a contract research organization (CRO) to expedite their clinical trials. The study sponsor's statistical analysis,as well as other activities, did not coincide with EDC or vendor data review timelines. To assist with this, Worldwide Clinical Trials was selected to conduct a Phase IIa study evaluating the safety, tolerability, and pharmacokinetics of their innovative IPF treatment.